Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

Raje, Noopur; G. Berdeja, Jesús; Lin, Yi; S. Siegel, David; Jagannath, Sundar; Madduri, Deepu; Liedtke, Michaela; Rosenblatt, Jacalyn; V. Maus, Marcela; Turka, Ashley; Lam, Lyh-Ping; A. Morgan, Richard; M. Friedman, Kevin; Massaro, Monica; Wang, Julie; Russotti, Greg; Yang, Zhihong; Campbell, Timothy; Hege, Kristen; Petrocca, Fabio; Travis Quigley, M.; C. Munshi, Nikhil; N. Kochenderfer, James

doi:10.1056/nejmoa1817226

Public

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

Published in New England Journal of Medicine • May 1, 2019

Authors:

Noopur Raje

Jesús G. Berdeja

Yi Lin

Abstract

BACKGROUND: Preclinical studies suggest that bb2121, a chimeric antigen receptor (CAR) T-cell therapy that targets B-cell maturation antigen (BCMA), has potential for the treatment of multiple myeloma. METHODS: CAR+ T cells in the expansion phase. Patients had received at least three previous lines ...

Subject

Chimeric antigen receptor

CAR T-cell therapy

Multiple myeloma

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!